DIA Mission
DIA fosters innovation to improve health and well-being worldwide by:
- Providing invaluable forums to exchange vital information and discuss current issues related to healthcare products, technologies, and services;
- Delivering customized learning experiences;
- Building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates; and
- Offering a multidisciplinary neutral environment, respected globally for integrity and relevancy.
DIA Vision
Our Annual Updates
Our Leadership
-
John A. Roberts,
MBA •Chair DIA
President and Chief Executive Officer
Cancer Genetics, Inc. (CGI) -
Joseph Scheeren,
PharmD •Chair-Elect DIA
Senior Advisor R&D
Bayer AG -
Jeffrey S. Payne,
CPA, CGMA •Secretary/Treasurer DIA
Chief Financial Officer
Katabat -
Barbara Lopez Kunz,
MS • Global Chief Executive
DIA
-
Gesine Bejeuhr,
PhD •Director DIA
Senior Manager, Regulatory Affairs/Quality
vfa, the Association of Research-based Pharmaceutical Companies -
Andrzej Czarnecki,
MD, PhD, DSc •Director DIA
Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety
Eli Lilly and Company, Ltd. -
Angelika Joos,
MPharm •Director DIA
Executive Director, Global Regulatory Policy
Merck Sharp & Dohme (Europe) Inc. -
Judith Ng-Cashin,
MD •Director DIA
Chief Scientific Officer
Syneos Health -
Michael Rosenblatt,
MD •Director DIA
Chief Medical Officer
Flagship Pioneering -
Jonathan Sheldon,
PhD •Director DIA
Senior Vice President
QIAGEN -
Lingshi Tan,
PhD •Director DIA
Chairman and Chief Executive Officer
dMed Company Limited -
Rebecca Vermeulen,
RPh •Director DIA
Head, Product Development Medical Affairs Customer Strategy
F. Hoffmann-La Roche Ltd.
-
John A. Roberts,
MBA • Chair, Executive Committee
-
Jeffrey S. Payne,
CPA • Member, Executive Committee -
Joseph Scheeren,
PharmD • Member, Executive Committee -
Barbara Lopez Kunz,
MS • Member, Executive Committee
-
Lingshi Tan,
PhD • Chair, Audit Committee -
Gesine Bejeuhr,
PhD • Member, Audit Committee -
Andrzej Czarnecki,
MD, PhD, DSc • Member, Audit Committee -
Judith Ng-Cashin,
MD • Member, Audit Committee
-
Gerald J. Dal Pan,
MD • Chair, Council of Regulators
Liaison Committee
US Food and Drug Administration Liaison to the DIA Board -
Peter Bachmann,
PhD • Council of Regulators
Liaison Committee
European Medicines Agency Liaison to the DIA Board -
Yoshiaki Uyama,
PhD • Council of Regulators
Liaison Committee
Japan Pharmaceuticals and Medical Devices Agency Liaison to the DIA Board
-
Catherine Parker • Council of Regulators
Health Canada Liaison to the DIA Board -
Mike Ward • Council of Regulators
World Health Organization Liaison to the DIA Board -
Yee Hoo Looi,
PhD • Council of Regulators
Health Sciences Authority Singapore Liaison to the DIA Board -
Nam-Hee Lee,
PhD • Council of Regulators
Ministry of Food and Drug Safety Liaison to the DIA Board
-
Barbara Lopez Kunz,
MS • Global Chief Executive -
Bayard G. Gardineer,
MS, CPA • Chief Financial Officer -
Elisabeth Svensson • Senior Vice President, Global Marketing & Business Development
-
Timothy Hess • Global Director of IT
-
Thomas Bols • Senior Vice President & Managing Director
DIA EMEA -
Youngshin Lee,
PhD • Senior Vice President & Managing Director
DIA South Korea and ASEAN -
Sudip S. Parikh,
PhD • Senior Vice President & Managing Director
DIA Americas -
Akio Uemura,
PhD • Senior Vice President & Managing Director
DIA Japan -
Carol Zhu,
RPh, MBA • Senior Vice President & Managing Director
DIA Greater China
A History of Accomplishment
Starting with the controversy over the drug Thalidomide, DIA’s founders - a group of 30 pharmaceutical professionals, medical writers, and academics - came together to create a platform for necessary global communication and collaboration to solve a healthcare threat to unborn children worldwide.
Today, professionals from 80 countries continue to engage with DIA through our unparalleled membership network, educational offerings, and professional development opportunities.